Medpace (NASDAQ:MEDP) Raised to Hold at Leerink Partnrs

Leerink Partnrs upgraded shares of Medpace (NASDAQ:MEDP) to a hold rating in a research note published on Monday,Zacks.com reports.

Other equities research analysts have also issued research reports about the company. Leerink Partners assumed coverage on Medpace in a research note on Monday. They set a “market perform” rating and a $330.00 price target on the stock. Robert W. Baird raised their price target on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a report on Monday, January 27th. Nine research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $376.30.

Medpace Trading Up 2.0 %

Shares of Medpace stock opened at $330.59 on Monday. Medpace has a 12 month low of $302.01 and a 12 month high of $459.77. The stock’s fifty day moving average price is $337.29 and its 200-day moving average price is $339.65. The firm has a market cap of $10.07 billion, a P/E ratio of 26.17, a P/E/G ratio of 3.81 and a beta of 1.47.

Medpace (NASDAQ:MEDP) last issued its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, topping analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. Analysts forecast that Medpace will post 12.29 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. R Squared Ltd acquired a new position in Medpace during the fourth quarter worth about $30,000. SBI Securities Co. Ltd. purchased a new stake in Medpace in the 4th quarter valued at about $31,000. Stone House Investment Management LLC purchased a new position in Medpace during the third quarter worth about $33,000. Jones Financial Companies Lllp increased its position in shares of Medpace by 2,750.0% during the fourth quarter. Jones Financial Companies Lllp now owns 114 shares of the company’s stock valued at $38,000 after acquiring an additional 110 shares during the last quarter. Finally, Lindbrook Capital LLC boosted its position in shares of Medpace by 27.6% during the 4th quarter. Lindbrook Capital LLC now owns 134 shares of the company’s stock worth $45,000 after purchasing an additional 29 shares during the period. 77.98% of the stock is owned by hedge funds and other institutional investors.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.